Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib

Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib

The availability of targeted therapies for molecular aberrations have substantially improved the outcomes of advanced non-small-cell lung cancer (NSCLC) patients harboring sensitive mutations. However, patients harboring uncommon epidermal growth factor receptor (EGFR) mutations such as G719X and L8...

Full description

Bibliographic Details
Main Authors: Zihan Zhou, Jie Huang, Ming Ding, Jing Huang, Ting Wu, Qun Wang, Shuhua Han, Yuan Lu
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Epidermal growth factor receptor (EGFR)
Non-small cell lung cancer (NSCLC)
Afatinib
L861Q
G719X
Compound mutations
Online Access:http://www.sciencedirect.com/science/article/pii/S221300712300148X

Internet

http://www.sciencedirect.com/science/article/pii/S221300712300148X

Similar Items